Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
1.750
-0.020 (-1.13%)
At close: Jun 24, 2026, 4:00 PM EDT
1.670
-0.080 (-4.57%)
Pre-market: Jun 25, 2026, 4:04 AM EDT
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
6.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.19M |
| BioAtla | 2.00M |
| PMGC Holdings | 1.27M |
| Can-Fite BioPharma | 405.00K |
| Silo Pharma | 72.10K |
| Cardio Diagnostics Holdings | 16.57K |
PPBT News
- 13 days ago - Purple Biotech presents new IM1240 data at EACR - TheFly
- 5 weeks ago - Purple Biotech files $200M mixed securities shelf - TheFly
- 2 months ago - Purple Biotech reports IM1240 demonstrates potent anti-tumor activity - TheFly
- 3 months ago - Purple Biotech announces collaboration with Converge Bio - TheFly
- 3 months ago - Purple Biotech regains compliance with Nasdaq - TheFly
- 3 months ago - Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright - TheFly
- 3 months ago - Purple Biotech CEO Gil Efron to step down in August - TheFly
- 3 months ago - Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year - TheFly